Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis

Company Overview

Telomir Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related diseases and conditions associated with cellular aging. The company’s research centers on telomeres, protective structures at the ends of chromosomes that generally shorten as cells divide and age.

Telomir’s lead investigational product is Telomir-1, a proprietary small-molecule compound designed to promote telomere lengthening and support cellular function. The company is evaluating its potential application in diseases associated with aging, including osteoarthritis and other conditions involving tissue degeneration. Telomir-1 remains an investigational therapy and is not an approved drug.

Telomir Pharmaceuticals is pursuing preclinical and clinical development activities intended to establish the safety and effectiveness of its technology. As a development-stage biotechnology company, its primary activities include drug discovery, research collaborations, and advancing Telomir-1 toward potential regulatory approval rather than marketing commercial products.

Key Stats

• Today's Range: $1.10 to $1.16
• 50-Day Range: $1.05 to $1.25
• 52-Week Range: $0.89 to $1.82
• Volume: 64,619 shs
• Average Volume: 149,423 shs
• Market Capitalization: $77.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Telomir Pharmaceuticals Stock Analysis - MarketRank™

Telomir Pharmaceuticals scored higher than 44% of companies evaluated by MarketBeat, and ranked 529th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Telomir Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Telomir Pharmaceuticals has a consensus price target of $4.00, representing about 257.1% upside from its current price of $1.12.

Amount of Analyst Coverage

Telomir Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Telomir Pharmaceuticals is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Telomir Pharmaceuticals is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Telomir Pharmaceuticals has a P/B Ratio of 6.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.44% of the float of Telomir Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 8.33.

Change versus previous month

Short interest in Telomir Pharmaceuticals has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Telomir Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Telomir Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.35

News Sentiment

Telomir Pharmaceuticals has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Telomir Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

1 people have searched for TELO on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Telomir Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Telomir Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.36% of the stock of Telomir Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Telomir Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TELO
• Previous Symbol: NASDAQ:TELO
• CIK: 1971532
• Web: telomirpharma.com
• Phone: (786) 396-6723
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Telomir Pharmaceuticals: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +257.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -102.70%
• Return on Assets: -90.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.16
• Quick Ratio: 16.16

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.17 per share
• Price / Book: 6.59

Miscellaneous

• Outstanding Shares: 68,780,000
• Free Float: 57,523,000
• Market Cap: $77.03 million
• Optionable: N/A
• Beta: -0.31